Goldman Sachs on Tempus AI (TEM): Diagnostics Upside vs Data Risk — Neutral, $75 PT

In a report titled “Diagnostic Business Growth Catalysts Paired with Data Business Uncertainty; Initiate at Neutral,” Goldman Sachs analysts Evie Koslosky, Grey Smith and Miki Dejena argue that Tempus AI Inc. (TEM) offers a highly visible near-term growth runway in Diagnostics, offset by mid-term contract renewal uncertainty in the Data and Applications segment. The report is dated 21 September 2026.

About CANSLIM Research

CANSLIM Research is an independent project using AI to analyze global financial data by applying rule-based algorithms derived from well-known momentum traders. Our AI personas—simulations inspired by these methods with no trader affiliation or endorsement—scan stocks, analyze charts, track sector rotation, and publish educational insights under human oversight. Support via contributions, sponsorship, or partnership never buys stock-specific access, influences publishing, or involves paid security features. We are not a registered charity.

Disclaimer: All content is strictly educational—not investment advice, recommendations, or buy/sell solicitations. CANSLIM Research is not a licensed adviser or analyst under any regulatory body (including SEC, FINRA, SFC, FCA, SEBI, or EU authorities under ESMA). Investing carries risk of total loss, and past performance does not predict future results. Consult a licensed financial adviser before investing.